Gilead Sciences (NASDAQ:GILD) Given New $123.00 Price Target at Royal Bank Of Canada

Gilead Sciences (NASDAQ:GILD) had its price target increased by Royal Bank Of Canada from $118.00 to $123.00 in a report released on Tuesday,MarketScreener reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Wolfe Research lifted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $157.81.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $138.80 on Tuesday. The company has a 50 day moving average of $145.10 and a 200 day moving average of $130.01. The stock has a market cap of $172.28 billion, a P/E ratio of 20.50, a P/E/G ratio of 1.83 and a beta of 0.39. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the company earned $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 299,280 shares of company stock valued at $42,820,550. Insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently made changes to their positions in the business. J. Derek Lewis & Associates Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $346,000. Rockefeller Capital Management L.P. raised its holdings in Gilead Sciences by 34.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 88,893 shares of the biopharmaceutical company’s stock valued at $10,911,000 after buying an additional 22,559 shares during the last quarter. World Investment Advisors raised its holdings in Gilead Sciences by 12.7% during the 4th quarter. World Investment Advisors now owns 31,753 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 3,589 shares during the last quarter. Meadowbrook Advisors Group LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $302,000. Finally, Larry Mathis Financial Planning LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $593,000. 83.67% of the stock is currently owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline: Gilead agreed to acquire Tubulis for up to $5.0B ($3.15B upfront, up to $1.85B in milestones), adding a next‑generation ADC platform and lead candidate TUB‑040 (Phase 1b/2 for platinum‑resistant ovarian cancer and NSCLC). The transaction is expected to close in Q2 2026 and Tubulis will operate inside Gilead post‑close — a tangible pipeline boost that can extend future oncology revenue. Business Wire
• Positive Sentiment: Analyst support: Bernstein put a Buy on Gilead, signaling conviction that recent M&A and pipeline moves improve medium‑term prospects — a positive endorsement that can underpin investor confidence. Globe and Mail
• Neutral Sentiment: Street reactions are mixed: Some banks raised price targets (RBC nudged its target higher to $123) but maintained conservative ratings, leaving implied upside limited from some analysts’ perspectives. That keeps expectations calibrated even as the company spends on deals. MarketScreener
• Neutral Sentiment: Macro/sector context: Broad market weakness today and healthcare sector headlines (Medicare rate moves, sector M&A activity) are weighing on stocks generally; Gilead’s move is part of a wider Q1 surge in pharma M&A. Yahoo / Sector roundup
• Negative Sentiment: Execution and strategy concerns: Commentary frames recent M&A as partly defensive — “more about survival” — and investors may be worried about integration risk, high upfront cost and contingent milestones. These concerns can pressure the share price in the short term despite long‑term pipeline logic. Moby / Yahoo

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.